Regenica Biosciences

Regenica Biosciences is a clinical-stage biotechnology company focused on the development of regenerative therapies for aesthetics and wound healing. The company utilizes a proprietary technology platform that mimics the embryonic environment to produce a naturally secreted, hypoxia-induced multipotent stem cell-conditioned media. This media contains a complex mixture of growth factors and proteins, such as VEGF and follistatin, which are essential for tissue regeneration and hair follicle stimulation. Its lead therapeutic candidate is a hair stimulating complex (HSC) currently being evaluated for the treatment of androgenetic alopecia. Led by regenerative medicine pioneer Dr. Gail Naughton, the company aims to provide next-generation solutions for skin rejuvenation and hair regrowth.